Goldman Sachs Group Inc Catalyst Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$0.19 - $0.64 $13,284 - $44,747	-69,918 Reduced 76.55%	21,423 $4,000
Q1 2023 May 11, 2023	BUY	$0.19 - $0.64 $4,070 - $13,710	21,423 New	21,423 $4,000
Q3 2022 May 14, 2024	SELL	$0.49 - $1.95 $13,623 - $54,215	-27,803 Reduced 23.34%	91,341 $46,000
Q3 2022 Nov 10, 2022	SELL	$0.49 - $1.95 $13,623 - $54,215	-27,803 Reduced 23.34%	91,341 $0
Q2 2022 May 14, 2024	BUY	$0.36 - $1.78 $42,891 - $212,076	119,144 New	119,144 $212,000
Q2 2022 Aug 15, 2022	BUY	$0.36 - $1.78 $659 - $3,260	1,832 Added 1.56%	119,144 $212,000
Q1 2022 May 16, 2022	SELL	$0.51 - $1.0 $62,882 - $123,299	-123,299 Reduced 51.24%	117,312 $77,000
Q4 2021 Feb 14, 2022	BUY	$0.91 - $4.16 $72,718 - $332,425	79,910 Added 49.73%	240,611 $220,000
Q3 2021 Nov 10, 2021	BUY	$3.78 - $5.18 $607,449 - $832,431	160,701 New	160,701 $660,000

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.